Introduction
============

Surgical site infection is one of the most common postoperative complications, occurring in at least 5% of all patients undergoing surgery and 30-40% of patients undergoing abdominal surgery, depending on the level of contamination.[@ref1] [@ref2] Development of a surgical site infection has a large impact on mortality and morbidity as well as healthcare costs.[@ref3] [@ref4] In the United Kingdom, length of stay in hospital is typically doubled and additional costs per patient of between £814 and £10 523 (€950 (\$1237) and €12 300 (\$16 000)) have been estimated, the variability depending on the type of surgery and the severity of the infection.[@ref5] [@ref6] [@ref7] The ancillary costs from time off work, reduced health related quality of life, dissatisfaction in patients, and litigation costs for the healthcare provider have been explored less extensively, but the little evidence available confirms a detrimental effect.[@ref8]

As most infections are the result of wound contamination by endogenous bacteria from the patient's skin, mucous membranes, or hollow viscera, the concept of using a physical barrier to cover the cut edges of the wound has been revisited by surgeons many times over the past half century. This protection can take the form of a wound edge protection device or "wound guard" that is inserted into the wound for the duration of the operation. There are several different devices on the market but they have the same basic design---a semirigid plastic ring placed into the abdomen through the laparotomy wound to which an impervious drape is circumferentially attached. This plastic drape comes up and out of the wound on to the skin surface, thus protecting the cut edges of the wound (fig 1)[](#fig1){ref-type="fig"}. Wound edge protection devices create a physical barrier between the abdominal wound edges and viscera, visceral contents, contaminated instruments, and gloves, thereby reducing accumulation of endogenous and exogenous bacteria on the wound edges. There have been six single centre and one multicentre trial, totalling around 1300 patients, which showed benefit from the use of a device and reporting a reduction in infections from 12-25% down to as low as zero in some series.[@ref9] [@ref10] [@ref11] [@ref12] [@ref13] [@ref14] [@ref15] Despite this their use is not discussed in the current UK clinical guidelines and they have not become established in routine clinical practice.

![**Fig 1** Wound edge protection device being used during surgery via midline laparotomy incision](pint010255.f1_default){#fig1}

We assessed the clinical effectiveness of wound edge protection devices in reducing rates of infection at the site of surgery in patients undergoing open abdominal surgery to evaluate the impact on patients' health related quality of life and length of hospital stay. We also carried out a cost effectiveness analysis, which will be reported elsewhere.

Methods
=======

Study design and patients
-------------------------

The ROSSINI (Reduction Of Surgical Site Infection using a Novel Intervention) trial was a prospective, multicentre, observer blinded, randomised controlled trial with stratification according to baseline infection risk.[@ref16] It was conducted from February 2010 to January 2012 at 21 National Health Service (NHS) hospitals across the UK.

This investigator initiated trial was conceived by the West Midlands Research Collaborative, a trainee led surgical research group who designed, disseminated, and managed the trial in conjunction with the Primary Care Clinical Research and Trials Unit and the Birmingham Clinical Trials Unit at the University of Birmingham.

Patients aged over 18 undergoing laparotomy for any surgical indication through any major incision in both elective and emergency settings were eligible for enrolment. Laparoscopic or laparoscopic assisted procedures were excluded, as were patients who had undergone a previous laparotomy within three months.

Randomisation and masking
-------------------------

Enrolled patients were randomly assigned through a concealed centralised secure web based system in a 1:1 ratio to either the control arm (standard intraoperative care) or the intervention arm (standard intraoperative care plus use of a wound edge protection device during the intra-abdominal part of the operation). Randomisation was performed when the patient was in the anaesthetic room immediately before surgery by using a secure online system provided by the University of Birmingham. To help match the two arms, randomisation was stratified according to the urgency of surgery, likelihood of opening a viscus, and likelihood of creating a stoma, with the use of a minimisation procedure. The in theatre surgical team were aware of arm allocation but only after induction of anaesthesia. No information about arm allocation was recorded in the clinical or operation notes, and the patient, ward staff, and clinicians undertaking the reviews of postoperative wounds were fully blinded to the group assignments.

Surgeons were free to undertake their other usual intraoperative interventions if they wanted, including their choice of antibiotic, skin preparation agent, use of adhesive incise drapes, and/or towels on the wound edges; these details were prospectively recorded and formed part of a planned secondary analysis. The device used (3M Steri-Drape Wound Edge Protector) was available in three different sizes at each site to enable an appropriate sized device to be selected for the laparotomy wound if the patients was allocated to the intervention arm.

Efficacy outcomes
-----------------

The primary endpoint was occurrence of superficial surgical site infection within 30 days after the operation. Diagnosis was based on criteria developed by the Centers for Disease Control (CDC).[@ref17] All wound assessors were experienced in the appraisal of postoperative wounds and were provided with standardised criteria and instructions regarding assessment. Centralised meetings to update investigators were held throughout the trial, included training in wound assessment, and each unit received a site visit on opening, which included training of local investigators. Additional standardisation of assessment was provided with a dedicated online e-learning module and quiz, developed for this study to minimise variability between assessors.

Secondary endpoints included health related quality of life, length of hospital stay, cost effectiveness, and the clinical efficacy of the device in relation to the degree of contamination, patient comorbidities, and operative demographics. This information was recorded contemporaneously on standardised clinical report forms.

Data on health related quality of life were collected at baseline, five to seven days, and 30 days with the validated EuroQol (EQ-5D 3L) tool.[@ref18] Questionnaires were paper based and completed by the patient. The principal analysis was the change in overall health related quality of life assessed by the EQ-5D~index~ score at 30 days.[@ref19] Data on resource use were collected for 30 days according to a standardised protocol.

Procedures
----------

Preoperative evaluation included the prospective assessment and recording of demographic data related to the patient and comorbidity. Operative details, including any deviation from allocation, were recorded immediately after the operation.

A trained blinded reviewer formally assessed the wound on day five to seven or at discharge if the patient left hospital earlier. A second formal wound review was performed at 30 to 33 days, which involved the patient returning to hospital for a physical review of the wound. At this same visit, patients also completed a self reported questionnaire with the study investigator to identify any occurrence of surgical site infection during the intervening period between the two clinician assessments. The questionnaire was based on the Health Protection Agency surgical site infection surveillance system (HPA SSISS), which is also based on the original CDC definitions. To maximise completeness of follow-up, trial research staff carried out home visits to the small number of patients who were unable to return to hospital for their second formal wound review because of infirmity or geographical distance.

Investigators who were blinded to the group assignments assessed the seriousness of all reported adverse events and determined if they were related to the study and/or the intervention.

Statistical analysis
--------------------

We hypothesised that the use of wound edge protection devices in adults undergoing laparotomy would result in a 50% reduction in the infection rate based on a conservative appraisal of evidence available from other trials.[@ref10] [@ref11] Assuming a conservative baseline infection rate of 12%,[@ref20] [@ref21] we needed 710 patients to confirm this effect with a two sided α of 5% and 80% power. The recruitment target was extended to 750 patients to accommodate a potential 5% dropout rate. Results were analysed according to intention to treat. Analyses were performed with SAS version 9.2 and R Statistical software (v2.14). Dichotomous outcomes (incidence of surgical site infection within 30 days) were analysed with the use of non-linear mixed models, which included stratification variables (plan to open a viscus, create a stoma, and elective *v* urgent surgery) as patient level covariates and surgeons as random effects. The difference in EQ-5D~index~ score by treatment group at 30 days was assessed with a mixed model that included baseline EQ-5D~index~ score and stratification variables as patient level covariates and surgeons as random effects. Time to discharge from hospital was estimated according to the Kaplan Meier method and analysed with the use of Cox proportional hazard model, which included stratification variables as covariates. The initial model was developed in SAS v 9.2, with surgeons subsequently included as random effects with the frailty term in R Statistical Software. Complete case analyses were undertaken for the data on health related quality of life. For those patients who died within 30 days of surgery we carried forward the last available wound assessment, unless no information was available in which case they were treated as lost to follow-up.

Results
=======

Study participants
------------------

From February 2010 to January 2012 we enrolled 760 patients from 21 UK centres and randomised 382 to the wound edge protection device group and 378 to the control group (fig 2).[](#fig2){ref-type="fig"} Of these, 376 and 373, respectively, underwent laparotomy and were included in the study. Seven patients in each group were subsequently lost to follow-up. Patients' demographics (table 1)[](#tbl1){ref-type="table"}, comorbidities, and operation characteristics (table 2)[](#tbl2){ref-type="table"}, including degree of contamination and NNIS risk index, did not differ substantially between the two groups at baseline.

![**Fig 2** Trial profile of patients in study of effect of wound edge protection devices during laparotomy](pint010255.f2_default){#fig2}

###### 

Characteristics of patients undergoing laparotomy with and without use of a wound edge protection device (WEPD). Figures are numbers (percentage) of patients unless specified otherwise

  Characteristic                             WEPD (n=376)       Control (n=373)
  ------------------------------------------ ------------------ ------------------
  Median (IQR) age (years)                   66.4 (54.8-74.7)   64.2 (55.5-72.8)
  Men                                        200 (53.2)         193 (51.7)
  Median (IQR) BMI                           26.5 (23.1-30.0)   26.0 (23.1-29.1)
  Median (IQR) serum albumin concentration   41.0 (34.0-44.0)   40.0 (35.0-44.0)
  Diabetes                                   62 (16.5)          51 (13.7)
  Current smoker                             64(17.0)           57 (15.3)
  Known ongoing malignancy at any site       241 (64.1)         241 (64.6)
  Median (IQR) baseline EQ-5D\*              0.81 (0.69-1)      0.85 (0.73-1)
  Urgency of operation:                                         
  Elective                                   181 (48.1)         183 (49.1)
  Expedited                                  117(31.1)          117(31.4)
  Urgent                                     75 (20.0)          71 (19.0)
  Immediate                                  3 (0.8)            2 (0.5)
  ASA grade:                                                    
  1                                          36 (9.6)           49 (13.1)
  2                                          203 (54.0)         186 (49.9)
  3                                          113 (30.1)         95 (25.5)
  4                                          4 (1.1)            7 (1.9)
  5                                          0 (0.00)           1 (0.3)
  Unknown                                    20 (5.3)           35 (9.4)

IQR=interquartile range, BMI=body mass index, EQ-5D=EuroQol health related quality of life score, ASA=American Society of Anaesthesiologists.

\*Measured in 359 in WEPD group and 351 in control group.

###### 

Procedural characteristics in patients undergoing laparotomy with and without use of a wound edge protection device (WEPD). Figures are numbers (percentage) of patients unless specified otherwise

  Characteristic                         WEPD (n=376)    Control (n=373)
  -------------------------------------- --------------- -----------------
  Operation site:                                        
  Large bowel                            247 (65.7)      237 (63.5)
  Small bowel                            34 (9.0)        48 (12.9)
  Hepatobiliary                          77 (20.5)       72 (19.3)
  Gastric                                15 (4.0)        8 (2.1)
  Cholecystectomy                        1 (0.3)         2 (0.5)
  Vascular                               1 (0.3)         0
  Abdominal hysterectomy                 0               2 (0.5)
  Unknown                                1 (0.3)         4 (1.1)
  Stoma created                          109 (29.0)      106 (28.4)
  Skin prep used:                                        
  Chlorhexidine                          136 (36.2)      135 (36.2)
  Aqueous Betadine (povidone-iodine)     215 (57.2)      197 (52.8)
  Alcoholic Betadine (povidone-iodine)   16 (4.3)        29 (7.8)
  Towels/mops used on wound edges        42 (11.2)       78 (20.9)
  Degree of contamination:                               
  Clean                                  24 (6.4)        31 (8.3)
  Clean-contaminated                     275 (73.1)      268 (71.9)
  Contaminated                           48 (12.8)       48 (12.9)
  Dirty                                  29 (7.7)        25 (6.7)
  Median (IQR) duration of surgery (h)   3.0 (2.0-4.0)   2.73 (2.0-4.0)
  Median (IQR) NNIS index\*              1 (0-1)         1 (0-1)
  Prophylactic antibiotic given:                         
  On induction                           321 (85.4)      322 (86.3)
  During procedure                       25 (6.7)        18 (4.8)
  Grade of operating surgeon:                            
  Consultant                             302 (80.3)      280 (75.1)
  Trainee                                69 (18.4)       82 (22.0)
  Grade of surgeon closing fascia:                       
  Consultant                             186 (49.5)      197 (52.8)
  Trainee                                182 (48.4)      157 (42.1)

\*NNIS index=national nosocomial infections surveillance index.

Surgical site infections
------------------------

In total, 184 patients experienced a surgical site infection within 30 days of surgery, 91/369 (24.7%) in the device group and 93/366 (25.4%) in the control group (odds ratio 0.97, 95% confidence interval 0.69 to 1.36; P=0.85) (table 3).[](#tbl3){ref-type="table"} The results were consistent across the assessments made at different time points within the study and by different observers, with both the formal assessments of wounds by clinicians and the patients' self reported data showing no difference on post hoc analysis (fig 3)[](#fig3){ref-type="fig"}. Furthermore, we observed no significant reduction in infection rate within 30 days by treatment group in any of the prespecified subgroup analyses (fig 4).[](#fig4){ref-type="fig"}

###### 

Primary and secondary endpoints in patients undergoing laparotomy with and without use of a wound edge protection device (WEPD). Figures are numbers (percentage) of patients unless specified otherwise

  Outcome                                        WEPD            Control         Estimate (95% CI)        P value
  ---------------------------------------------- --------------- --------------- ------------------------ ---------
  **Primary outcome**                                                                                     
  Surgical site infection (SSI) within 30 days   91/369 (24.7)   93/366 (25.4)   0.97\* (0.69 to 1.36)    0.85
  **Secondary outcomes**                                                                                  
  Mean (SD) EQ-5D                                0.69 (0.29)†    0.69 (0.30)‡    0.001§ (−0.04 to 0.05)   0.95
  Median (IQR) length of hospital stay (days)    9 (6 to 15)     9 (6 to 14)     1.03¶ (0.88 to 1.19)     0.82
  Degree of wound contamination:                                                                          
  Clean                                          8/24 (33.3)     7/29 (24.1)     1.76\* (0.40 to 7.70)    0.43
  Clean-contaminated                             61/269 (22.7)   63/263 (24.0)   0.94\* (0.62 to 1.42)    0.76
  Contaminated                                   10/48 (20.8)    15/48 (31.3)    0.601\* (0.23 to 1.63)   0.31
  Dirty                                          12/28 (42.9)    7/25 (28.0)     1.85\* (0.50 to 6.87)    0.33

IQR=interquartile range, EQ-5D= EuroQol health related quality of life score.

\*Odds ratio.

†n=318.

‡n=313.

§Difference in means.

¶Hazard ratio.

![**Fig 3**Rates of surgical site infection by treatment group within 30 days in patients allocated to surgery with use of wound protection device (WEPD) or standard care](pint010255.f3_default){#fig3}

![**Fig 4**Subgroup analyses for primary outcome in patients allocated to surgery with use of wound protection device (WEPD) or standard care](pint010255.f4_default){#fig4}

Deviations from protocol and sensitivity analyses
-------------------------------------------------

A wound edge protection device was used in four patients randomised to the control arm and was not used in 29 patients randomised to receive the device: in 11 cases the device was unavailable or of inappropriate size for the procedure, in six cases the nature of the surgery or the peritoneal cavity prevented insertion, in 12 cases the surgical team forgot to use the device. A post hoc sensitivity analysis was undertaken to explore the effect of treatment cross over on the estimate of effectiveness of the device. In this "best case scenario" analysis (in which a maximal benefit from use of device is assumed), all patients allocated to the control group but in whom a device was used were assumed to have had an infection within 30 days, conversely those patients randomised to device use in whom a device was not used were assumed to have had no event. In this extreme case results of the analysis of the effect of the device were still non-significant (odds ratio 0.77, 95% confidence interval 0.54 to 1.09; P=0.14). Further exploratory analyses were also undertaken to assess any potential learning curve effects with use of the device. We found no significant association between the rate of surgical site infection and number of wound edge protection devices used, both at unit and individual surgeon level.

Secondary outcomes
------------------

We observed no significant difference in health related quality of life (mean difference in EQ-5D score 0.001, 95% confidence interval −0.043 to 0.046; P=0.95), and the time to first discharge from hospital was comparable across treatment groups (hazard ratio 1.03, 95% confidence interval 0.88 to 1.19; P=0.82). There were no significant differences in healthcare use between the trial arms in both secondary and primary care settings.

Eleven patients in each group were readmitted to hospital with a surgical site infection, the remaining infections were managed in the community or before discharge from their index admission.

None of the prespecified secondary analyses exploring the efficacy of the wound edge protection device in reducing the likelihood of infection at the site of surgery according to degree of abdominal contamination, patient comorbidity, duration of surgery, or grade of surgeon closing the wound showed any significant difference (table 2 and fig 4).[](#tbl2){ref-type="table"} [](#fig4){ref-type="fig"}

Adverse events
--------------

In total 20 patients died within 30 days of surgery (12 in control group; eight in device group). No adverse events associated with the use of the device were reported.

Overall effects of infection at the site of surgery (both arms)
---------------------------------------------------------------

Patients without an infection had a significantly shorter duration of initial stay in hospital (median days 9 (interquartile range 6-13) in control group and 8 (6-14) in device group) than those with an infection (10 (7-22) and 10 (7-20)).

The 184 patients who developed a surgical site infection consumed significantly more resources in the primary care setting compared with the uninfected patients, reflected in the mean number of interactions with community healthcare professionals (general practitioner, district nurse, practice nurse): mean 8.03 (SE 0.66) in the patients with infection and 3.26 (0.28) in the patients without (P\<0.001). EQ-5D scores also indicated a 11% reduction in health related quality of life at 30 days in the patients who developed an infection (P\<0.001).

Discussion
==========

The ROSSINI trial has found that the use of wound edge protection devices during laparotomy does not result in a reduced rate of surgical site infection. This finding was consistent across a range of patient subgroups and for early and late infection. The use of resources, both in hospital and subsequently in the community, was comparable across both arms of the study. These findings differ from results of most previous studies and from two published meta-analyses.[@ref22] [@ref23] Of the previous studies, only two were multicentre and all displayed considerable potential risk of bias. These limitations have been expressed in the expert literature and the need for a large multicentre trial identified.[@ref24]

The reasons behind the variance between the ROSSINI trial and several previous published studies are uncertain. The two previously published multicentre randomised controlled trials reported from a combined total of six units and 270 patients. Nystrom and colleagues, concurring with ROSSINI findings, reported data from 140 patients undergoing elective colorectal surgery at two centres and found no benefit from the use of a device (rate of infection of 10% in the intervention arm and 9% in the control group).[@ref25] More recently, however, Reid and colleagues reported on 130 elective colorectal resections at four Australian centres and found a significant reduction in surgical site infection in the device arm, with 3/64 (4.7%) developing infection versus 15/66 (22.7%) in the control arm (P=0.004).[@ref15] Our trial reported included 760 patients across 21 centres (62% colorectal operations) and found no demonstrable benefit for any subgroup of patients.

Strengths and weaknesses
------------------------

One concern, particularly in an interventional study, is blinding the assessment to avoid bias. We incorporated several design points to overcome this, including electronic randomisation (including a minimisation procedure), group concealment, blinding of wound assessors and patients, and a robust quality assured follow-up protocol including training in wound assessment. Previous studies of wound edge protection devices have not undertaken all such measures.

The patient groups in our study were well matched with no significant over-representation of any patient or operative characteristic in either arm. At 25.4%, the baseline infection rate was significantly higher than the conservative 12% predicted baseline rate. This provided increased power to detect potential benefit. Traditionally quoted rates of infection have previously been based on passive and retrospective surveillance and so were prone to under-reporting. The apparent incidence of infection increases significantly, at least doubling in some reports, when outpatient follow-up is undertaken and/or appropriately trained wound observers are used.[@ref7] [@ref26] [@ref27] [@ref28] Recent UK data have reported that the time to onset of infection after gastrointestinal operations is eight to nine days (interquartile range 5-12 days)[@ref29] and as such will often present after the patient has been discharged from hospital. The higher infection rates (across all sites in our trial) are therefore likely to be related to the policy of more intensive and longer follow-up. Our infection rate is consistent with the rates in several recent studies that also used active wound monitoring and reviews after discharge for colorectal surgery, with reported rates of 25%,[@ref30] 25.3%,[@ref31] and 24.9%.[@ref32]. The fact that the length of hospital stay, use of health resources, and health related quality of life were all significantly and detrimentally affected in patients with a diagnosis of an infection suggests that these patients were truly affected by a condition that impacted on their postoperative recovery and counters the proposition that that the trial processes might have overdiagnosed occurrence of infection at the site of surgery, masking an underlying benefit.

A further notable finding in our trial is the higher than expected infection rate in clean and clean-contaminated operations, which shows little difference to the other contamination groups and is in contrast to routinely presented data. Closer examination of these groups found that the combined infection rate for clean and clean-contaminated patients at the wound review on day five to seven was only 6.5% (compared with 12.1% at this stage for the contaminated and dirty wounds). Most infections at the site of surgery in these patients were therefore diagnosed after discharge. This could suggest that the apparently lower infection rates in this group of patients reported elsewhere represent observational bias because of the infections occurring after discharge, perpetuated by patients undergoing these more minor, and often elective, operations having a generally shorter length of hospital stay. In addition, the "clean" operations entailed longer and more complex operations than those typically reported in this category: 32% underwent adhesiolysis and 12% incisional hernia repair, which are, by definition "re-do" longer operations and often performed in the acute setting. The overall proportion of clean operations performed as an emergency was 53%. Together these factors might also have contributed to the higher than expected infection rate in this group.

All outcome data have been presented in full for the trial. As per accepted best practice, we primarily undertook an intention to treat analysis, but it is important to also note that the sensitivity analysis did not identify any potential difference in result from treatment cross over.

It is possible that a flaw in the ROSSINI trial has masked a positive result. Key to this is the blinding process, the use of the wound edge protection devices, and the measurement of the endpoint. We instituted an online blinding process in theatre so the patient and wound assessor were unable to introduce bias. We compared the effect of use of the devices in high and low recruiting centres and found no difference between the two groups. Finally, the trial has identified a high wound infection rate, which was associated with additional use of health services to manage the wounds. This was, however, entirely equivalent between the two arms, both on the resources used and the timing of the infection treatment. These factors, taken with the large size and multiple centres in the ROSSINI trial would suggest the findings are robust.

How wound edge protection devices might work
--------------------------------------------

The presumptive primary method of action of the device is that the physical barrier formed by the impervious sheet covering the cut edges of the wound prevents endogenous and exogenous pathogens from coming into contact with the cut skin, fat, and fascia, thereby reducing likelihood of infection. Horiuchi and colleagues presented evidence supporting this theory, showing that these devices seem to protect the incision from bacterial invasion.[@ref33] It is therefore possible that a protective effect of the device could be real, but the pathogens responsible for surgical site infection could be introduced to the wound when the device is not in place---either on opening the wound before the device is inserted or on closing after the device has been removed. The latter would seem more likely as gloves, instruments, and surroundings will clearly be dirtier. The protocol for our trial did not stipulate changing of gloves, instruments, or drapes, which would not be standard practice in the UK. Evaluation of this practice in combination with a wound edge protection device might be worth considering.

We investigated only the single ring variant of the wound edge protection device. One recent pooled analysis of small single centre studies indicated a difference in outcomes between single ring and two ring devices, but there are no head to head data comparing the different designs. We therefore sought to answer the broader question of the effect of wound edge protection in general, but the suggestion that different device designs might provide greater physical barriers than others could warrant further investigation.

Implications
------------

Our findings directly challenge the conclusions of numerous smaller scale, largely single centre trials regarding the efficacy of device in reducing surgical site infection. We believe that this outcome is robust and as such feel that practice should change as the routine use of devices in this role cannot be recommended. This trial highlights the need for large scale rigorous and appropriately powered randomised trials to fully assess surgical interventions or devices before their true efficacy can be determined.

### What is already known on this topic

1.  Two systematic reviews have pooled multiple small randomised controlled trials exploring the use of wound edge protection devices to reduce surgical site infections after abdominal surgery and suggested an overall beneficial effect

### What this study adds

1.  Wound edge protection devices do not reduce rate of surgical site infection, health related quality of life, or length of stay in hospital compared with standard care
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